Ally Bridge Group’s Karyopharm Therapeutics KPTI Stock Holding History

Ally Bridge Group’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.39M	Buy	+250,000	New	+$1.91M	1.12%	27

Other funds holding KPTI

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CCM

Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Ally Bridge Group's KPTI Position: Q1 2023 in Review

Ally Bridge Group sold out of Karyopharm Therapeutics (KPTI) in Q1 2023, closing a stake of 59,775 shares — an estimated $3.05M sold.

Ally Bridge Group first reported a position in KPTI in Q3 2022 and held it in 2 quarters. The position peaked at $8.35M in Q3 2022. 129 funds tracked by Wall St. Rank hold KPTI as of Q1 2023.

Ally Bridge Group reported no remaining Karyopharm Therapeutics position as of Q1 2023 after selling out during the quarter.
Ally Bridge Group sold 59,775 Karyopharm Therapeutics shares in Q1 2023, an estimated $3.05M.
Ally Bridge Group first reported a position in Karyopharm Therapeutics in Q3 2022 and held it in 2 quarters.
Ally Bridge Group's Karyopharm Therapeutics position peaked at $8.35M in Q3 2022.
129 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2023.

Based on Ally Bridge Group's 13F filing for Q1 2023, filed 15 May 2023.